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is currently not recommended for CAV screening due to the limited accuracy reported by early studies. Technological
advances, however, might have resulted in improved test performance and might justify re-evaluation of this
recommendation.Methods A systematic review of Medline, Cochrane, and Embase for all prospective trials assessing CAV using CCTA was
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(97% vs. 91%, p ¼ 0.06) and NPV (99% vs. 97%, p ¼ 0.06) to detect signiﬁcant CAV with 64-slice compared with
16-slice CCTA. A patient-based analysis of 64-slice CCTA versus IVUS showed a mean weighted sensitivity and
speciﬁcity of 81% and 75% to detect CAV (intimal thickening >0.5 mm), whereas the PPV and NPV were 93% and
50%, respectively.Conclusions CCTA using currently available technology is a reliable noninvasive imaging alternative to coronary angiography
with an excellent sensitivity, speciﬁcity, and NPV for the detection of CAV. (J Am Coll Cardiol 2014;63:1992–2004)
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retransplantation 5 years after transplant occurs in 7% of the
recipients who develop CAV of any degree and in 50% of
the recipients who develop severe CAV (3,4).See page 2005The diagnosis of CAV has traditionally relied on the use
of conventional coronary angiography (CCAG) (4).
Although widely available and clinically accepted, it has the
disadvantages of being invasive and only providing visuali-
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1993understanding of the coronary wall anatomy and the disease
process in CAV (5). Its high sensitivity and negative pre-
dictive value made IVUS valuable for the assessment of
CAV in the investigational ﬁeld. Nonetheless, the routine
clinical use of IVUS as a screening tool for CAV is not
currently recommended, as it is unclear whether IVUS can
provide clinical incremental value over CCAG and func-
tional data. Furthermore, the use of IVUS is invasive,
costly, and can be time consuming (4). A technique that has
been viewed with enthusiasm in the assessment of CAV is
coronary computed tomography angiography (CCTA). It
has the advantages of being noninvasive, allows for visuali-
zation of all coronary arteries, and provides information
about the coronary artery wall. A small number of trials,
with a limited number of patients, suggested that the
diagnostic accuracy of CCTA in detecting CAV may be
similar to that of CCAG (6–10). Prior reviews assessing
the diagnostic accuracy of CCTA to detect CAV are
limited by incomplete data and technical limitations
(11,12). As a result of the limited data supporting the
diagnostic accuracy of CCTA to detect CAV and concernsFigure 1 Selection of Studies
Six studies were excluded from the ﬁnal analysis because they had incomplete data. CA
CCTA ¼ coronary computed tomography; IVUS ¼ intravascular ultrasound.about radiation exposure, its use
is not recommended for routine
surveillance of CAV by the
clinical practice guidelines (13).
Our aim was to closely examine
contemporary data on the accu-
racy of CCTA for the detection
of CAV through a meta-analysis
approach.Methods
Search strategy. We conducted
PubMed, Embase, and Cochrane
Central Register of Clinical Trials
searches for prospective studies
in which CCTA was used to
assess the presence and/or the
severity of CAV using the terms: (CTA OR CCTA OR
computed tomography OR coronary computed tomog-
raphy angiography OR computed tomography coronaryV ¼ cardiac allograft vasculopathy; CCAG ¼ conventional coronary angiography;
Table 1 Baseline Characteristics of Prospective Studies Evaluating the Diagnostic Accuracy of CCTA in the Assessment of CAV
First Author
(Ref. #), Year
Patients
(Initial Group) Male (%) Age (yrs)
BMI
(kg/m2)
Time After
Transplant
(Months)
Renal Function,
Scr (mg/dl)/eGFR
(ml/min/1.72 m2)
Use of
b-Blocker
Gold standard: CCAG
Carrascosa et al. (30), 2009 19 (24) 89 53 27 88 Mean Scr: 1.1  0.2 No
Iyengar et al. (8), 2006 19 (37) 74 58 NR NR Mean eGFR: 80  19 No
Nunoda et al. (26), 2010 13 (22) 77 35 NR NR NR No
Pichler et al. (32), 2008 44 (66) 90 58 27 102 NR
(Exclusion if Scr >2.0)
No
Romeo et al. (6), 2005 44 (53) 75 48 NR 91 NR
(Exclusion if Scr >2.8)
Yes
Schepis et al. (10), 2009 30 (41) 81 40 26 34 NR
(Exclusion if Scr >1.4)
No
Sigurdsson et al. (9), 2006 53 (54) 89 54 28 NR Mean Scr: 1.2  0.3 No
Usta et al. (31), 2009 10 (10) 80 52 27 73 Scr: 1.2–1.7: 40% of patients
<1.2: 60% of patients
Yes
Von Ziegler et al. (25), 2009 26 (28) 100 53 NR 92 Mean Scr: 1.2  0.2 Yes
Kepka et al. (27), 2012 20 (20) 75 48 25 NR Mean eGFR: 67.5 (45–90) Yes
Von Ziegler et al. (28), 2012 46 (51) 84 52 NR 83 Mean Scr: 1.2  0.2 Yes
Mittal et al. (29), 2013 130 (138) 78 52 27 144 eGFR: 30–59: 41% of patients
60: 59% of patients
No
Gold standard: IVUS
Carrascosa et al. (30), 2009 19 (24) 89 53 27 88 Mean Scr: 1.1  0.2 No
Gregory et al. (7), 2006 20 (20) 80 52 30 70 Mean Scr: 1.2  0.2 Yes
Schepis et al. (10), 2009 30 (41) 81 40 26 34 NR
(Exclusion if Scr >1.4)
No
Sigurdsson et al. (9), 2006 13 (54) 89 54 28 NR Mean Scr: 1.2  0.3 No
Continued on the next page
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1994angiography OR cardiac computed tomography angiog-
raphy OR coronary CT angiography OR coronary
computed tomography OR multi-slice computed tomog-
raphy OR multi-slice computed tomography angiography
OR multi-detector computed tomography) AND (CAV
OR cardiac allograft vasculopathy OR vasculopathy OR
transplant vasculopathy OR graft vasculopathy OR coro-
nary allograft vasculopathy OR coronary vasculopathy OR
chronic allograft vasculopathy). We limited our search to
humans and adults (>18 years of age) in peer-reviewed
journals from 1966 to 2013. No language restriction
was applied. The reference lists of bibliographies of
identiﬁed papers were also reviewed. Trials in the abstract
form without a published manuscript were excluded from
this analysis.Eligibility criteria. Eligible trials had to fulﬁll the
following criteria: 1) prospective study involving heart
transplant recipients who underwent CCTA to assess for
the presence of CAV in comparison to CCAG and/or
IVUS; 2) study allowed for sensitivity, speciﬁcity, negative
predictive value (NPV), and positive predictive value (PPV)
calculations; and 3) there was use of standardized cutoffs
for each test, or enough data were provided to calculate
diagnostic and predictive accuracies using these cutoffs.
Data extraction and quality assessment. Three inves-
tigators (O.W.-P., J.R., C.M.) independently assessed trial
eligibility and extracted data using standardized protocol
and reporting forms. Disagreements were resolved by con-
sensus. Characteristics of each trial, baseline demographics,
methods, interval between transplantation and CCTA,
Use of
Nitrate CT Slices
Heart Rate
(beats/min)
Contrast
Volume (ml)
Radiation
Dose (mSv)
Evaluable
Patients or
Segments (%)
CAV
Prevalence (%)
Analysis
(Patient- vs.
Segment-Based)
CAV
Deﬁnition
Gold standard: CCAG
No 16 90 100 10–13 98 9 Segment >50% stenosis
No 64 79 100 NR 100 53 (>0% stenosis)
5 (50% stenosis)
Patient >0% stenosis,
50% stenosis
Yes 16 and 64 NR 86–115*
0.7 ml/kgy
NR 100 20 (>0% stenosis)
6 (>50% stenosis)
Segment >0% stenosis,
>50% stenosis
No 16 87 100 NR Patient: 73
Segment: 94
Patient: 18
Segment: 2
Patient and segment 70% stenosis
No 16 70 70–90 3–8 Patient: 88
Segment: 96
Patient:
43 (>0% stenosis)
14 (50% stenosis)
Segment:
16 (>0% stenosis)
2 (50% stenosis)
Patient and segment >0% stenosis,
50% stenosis
No DSCT-64 80 60–80 10  2 96 16 Segment >0% stenosis
No 16 90 100 10  2 Patient: 100
Segment: 95
Patient: 30
Segment: 7
Patient and segment >50% stenosis
No 16 NR 100 6 100 40 (>0% stenosis)
20 (>50% stenosis)
Patient >0% stenosis,
>50% stenosis
No 64 86 90 NR Patient: 100
Segment: 81
Patient: 19
Segment: 3
Patient and segment 50% stenosis
Yes DSCT-64 85 68 13 Patient: 100
Segment: 84
Patient: 10
Segment: 1
Patient and segment >50% stenosis
No DSCT-64 88 NR NR Patient: 96
Segment: 99
Patient: 6
Segment: 1
Patient and Segment >50% stenosis
Yes 64 83 70–90 18 Patient: 96
Segment: 98
Patient:
42 (>0% stenosis)
15 (50% stenosis)
Segment:
12 (>0% stenosis)
3 (50% stenosis)
Patient and segment >0% stenosis,
50% stenosis
Gold standard: IVUS
No 16 90 100 10–13 100 25 Segment Intimal thickness
>0.5 mm
No 64 77 83  10 NR Patient: 100
Segment: 98
Patient: 80
Segment: 47
Patient and segment Intimal thickness
>0.5 mm
No DSCT-64 80 60–80 10  2 96 37 Segment Intimal thickness
>0.5 mm
No 16 90 100 10  2 100 33 Segment Proliferative changes
*Contrast volume used for 16-slice coronary computed tomography angiography (CCTA). yContrast volume used for 64-slice CCTA.
BMI ¼ body mass index; CAV ¼ cardiac allograft vasculopathy; DSCT ¼ dual-source computed tomography; eGFR ¼ estimated glomerular ﬁltration rate; NR ¼ not reported; Scr ¼ serum creatinine.
Table 1 Continued
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1995prevalence of CAV, and data required to evaluate the
diagnostic accuracy of CCTA were extracted. In instances
where data were not readily available, the main investigator
of that particular trial was approached to supply the relevant
information. The assessment of quality of each study was
done by evaluating 14 items considered relevant to the re-
view topic, on the basis of the Quality Assessment of
Diagnostic Accuracy Studies instrument (14). Two re-
viewers (J.R. and J.W.-P) independently assessed the quality
items, and discrepancies were resolved by consensus.
Statistical analysis. Sensitivities (number of stenotic cor-
onary segments estimated by the index test [CCTA]
divided by the total number of stenotic segments identiﬁed
by the reference standard [CCAG/IVUS]), speciﬁcities
(number of normal segments estimated by the index testdivided by the total number of segments without stenosis
identiﬁed by the reference standard), PPV (stenotic seg-
ments identiﬁed by index test conﬁrmed by reference
standard divided by the total number of stenotic segments
estimated by index test), and NPV (segments without
stenosis identiﬁed by index test conﬁrmed by reference
standard divided by the total of nonstenotic segments
estimated by index test) were calculated for every study.
Summary sensitivity and speciﬁcity were estimated using
both, a standard random effect model and a more recently
developed bivariate random effects model (15,16). The
bivariate approach assumed logit transforms of sensitivity
and speciﬁcity from individual studies are from a bivariate
normal distribution. The bivariate approach is considered
to be a better approach as compared with the standard
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1996summary receiver operating characteristics (ROC) ap-
proach because (17): 1) it assesses heterogeneity across
studies and provides a summary estimate of sensitivity
and speciﬁcity; 2) it models sensitivity and speciﬁcity jointly
so that a 95% conﬁdence ellipse around the summary esti-
mate can be calculated; 3) it allows a direct comparison
of sensitivity and speciﬁcity between methods; and 4) it
provides several choices to obtain a summary ROC
curve (15,16). The summary ROC curve was obtained
by transforming the regression line of logit sensitivity on
logit speciﬁcity into ROC space (15). Publication bias
was assessed for each analysis using Peter and Egger
methods. We assessed between-study heterogeneity
visually, by plotting sensitivity and speciﬁcity in the ROC
curves. Summary ROC curves and conﬁdence regions for
summary sensitivity and speciﬁcity were also drawn
(16,18). The analyses were conducted using standard
software (Stata 12, Stata Corporation, College Station,
Texas).
Sensitivity analysis. We further evaluated whether the
performance of each technique depends on features of the
technique and patient characteristics. A logistic regression
for each technique was used to model the sensitivity on these
factors.
Results
Study selection. We identiﬁed 2,830 papers, of which
1,672 abstracts were retrieved and reviewed for possible
inclusion (Fig. 1). Thirteen studies, enrolling 615 patients
(mean age 52  8.5 years; 83% male) and a total of 9,481
coronary segments fulﬁlled the inclusion criteria and were
included in the analysis (Table 1). These 13 studies allowed
for 34 comparisons. Six studies were excluded from the ﬁnal
analysis because they did not meet the inclusion criteria:
1 study did not use CCTA and CCAG in all patients,
CCAG was used only to conﬁrm abnormal CCTA ﬁnd-
ings (19), another study compared CCTA versus dobut-
amine stress echocardiography and only used CCAG in
patients with an abnormal result of either test (20), another
study provided no data to calculate diagnostic accuracies
(21), another study did not report demographic data,
number of segments and the speciﬁc numbers compared
with CCAG and IVUS (22), another study comparing 64-
slice and 256-slice CCTA versus CCAG reported the
diagnostic accuracy without differentiation between 64-
slice and 256-slice CCTA (23); and the last study was
conducted using 4-slice CCTA (24).
Baseline characteristics. Of the 13 studies, 8 studies
analyzing 410 patients (mean age 49  7.6 years; 81%
male) and 5,949 coronary segments evaluated CAV using
64-slice CCTA (7,8,10,25–29). Seven studies compared
64-slice CCTA with CCAG and 2 studies compared
64-slice CCTA with IVUS (7,10). Six studies analyzing 205
patients (mean age 50  8.0 years; 83% male) and 3,532
coronary segments evaluated CAV using 16-slice CCTA,with all of them using CCAG for comparison and 2 of them
also using IVUS for comparison (Table 1) (6,9,26,30–32).
Quality assessment. The selected studies showed overall
high-quality scores in all the 14 items of the Quality
Assessment of Diagnostic Accuracy Studies instrument.
Reporting was poor in 1 of the studies on item 13: “Were
uninterpretable/intermediate test results reported?” Un-
interpretable results are often not reported in diagnostic
accuracy studies. However, this may lead to the biased
assessment of the test characteristics. Bias will arise de-
pending on the possible correlation between uninterpretable
test results and the true disease status. If uninterpretable
results occur randomly and are not related to the true disease
status, these should have no effect on test performance. Two
papers did not provide sufﬁcient information regarding the
execution of the reference standard, which could affect the
reproducibility of the test results or its performance. Three
papers did not explain whether the reference (2 papers) or
index test (1 paper) were interpreted in a blinded fashion
(review bias), which might have led to inﬂated measures of
diagnostic accuracy (Figs. 2A and 2B).
Publication bias. Using Egger’s test, there was no indication
of publication bias for any of the analyzed techniques (p> 0.09
for all analyses). Likewise, the Peters test did not suggest
presence of publication bias (p > 0.15 for all analyses).
CCTA versus CCAG. Twelve studies evaluated the pres-
ence of CAV by CCTA using CCAG as the reference test.
CCTA was performed between 34 and 144 months (mean
88 months) after transplant. The mean heart rate at the time
of CCTA was 84 beats/min (range 70 to 90 beats/min) and
5 studies used beta-blockers for heart rate reduction. The use
of contrast media ranged from 60 to 115 ml and the radi-
ation dose from 3 to 18 mSv. The incidence of contrast
induced nephropathy was reported in most studies (n ¼ 9),
with no cases observed in the enrolled patients. Most studies
(n ¼ 10) used a 50% stenosis cutoff to determine the
presence of signiﬁcant CAV, except for 1 study that used
a 70% stenosis cutoff. Six studies used a >0% stenosis
cutoff to determine the presence of any CAV (Table 1).
Diagnostic accuracy of CCTA for the detection of anyCAV.
PATIENT-BASED ANALYSIS. Any CAV was found in 87 pa-
tients by means of CCAG, which represents a prevalence of
43%. The combined overall weighted mean sensitivity,
speciﬁcity, PPV, NPV, and accuracy for CCTA (64-slice
and 16-slice CCTA) were 97% (95% conﬁdence interval
[CI]: 92% to 100%), 81% (95% CI: 74% to 88%), 78%
(95% CI: 71% to 86%), 97% (95% CI: 93% to 100%), and
88% (95% CI: 84% to 93%), respectively (Fig. 3). Analyses
of the different measures of diagnostic accuracy, stratiﬁed
by the number of CCTA slices are shown in Table 2A.
There were no signiﬁcant differences in these measures
when 64-slice and 16-slice CCTA were compared.
SEGMENT-BASED ANALYSIS. A total of 384 segments had
evidence of any CAV by CCAG, which represents a prev-
alence of 13%. The combined overall weighted mean
Figure 2
Quality Assessment of Included CCTA Studies by the Quality Assessment of Diagnostic Accuracy Studies
(QUADAS) Instrument
Review authors’ judgment about each methodological quality item for each included study. (A) Methodological quality graph. (B) Methodological quality summary. Good (þ),
indeterminate (?) or poor () quality. CCTA ¼ coronary computed tomography angiography.
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1997sensitivity, speciﬁcity, PPV, NPV, and accuracy for CCTA
(64-slice and 16-slice) were 88% (95% CI: 85% to 92%), 89%
(95% CI: 88% to 90%), 55% (95% CI: 51% to 59%), 98%
(95% CI: 97% to 98%), and 90% (95% CI: 89% to 91%),
respectively (Online Fig. 1). Additional analyses, stratiﬁed by
the number of CCTA slices are shown in Table 2B. There
were no signiﬁcant differences in the measures of diagnostic
accuracy between 64-slice and 16-slice CCTA.
Diagnostic accuracy of CCTA for the detection of
signiﬁcant CAV. PATIENT-BASED ANALYSIS. Sixty-two pa-
tients had evidence of signiﬁcant CAV by CCAG, which
represents a prevalence of 16%. The combined overall mean
weighted sensitivity, speciﬁcity, PPV, NPV, and accuracy for
CCTA (64-slice and 16-slice) were 94% (95% CI: 87% to
100%), 92% (95% CI: 89% to 95%), 67% (95% CI: 59% to
76%), 99% (95% CI: 97% to 100%), and 94% (95% CI: 91%
to 96%), respectively (Fig. 4). Analyses of diagnostic accu-
racy, stratiﬁed by the number of CCTA slices are shown
in Table 3A. Although statistically there were no signiﬁcant
differences in the evaluated measures between 64-slice
and 16-slice CCTA, there was a trend toward improved
sensitivity (97% vs. 91%, p ¼ 0.06), NPV (99% vs. 97%,
p ¼ 0.06), and lower PPV (63% vs. 72%, p ¼ 0.06) with the
use of 64-slice CCTA.
SEGMENT-BASED ANALYSIS. A total of 174 segments had
signiﬁcant CAV by CCAG, which represents a prevalence
of 3%. The combined overall mean weighted sensitivity,
speciﬁcity, PPV, NPV, and accuracy for CCTA (64-slice
and 16-slice) were 86% (95% CI: 82% to 91%), 99% (95%CI: 98% to 99%), 73% (95% CI: 68% to 78%), 99% (95%
CI: 99% to 100%), and 99% (95% CI: 98% to 99%),
respectively (Online Fig. 2). Additional analyses, stratiﬁed
by the number of CCTA slices are shown in Table 3B.
There were no signiﬁcant differences in the measures of
diagnostic accuracy between 64-slice and 16-slice CCTA.
However, there was a trend toward lower PPV with 64-slice
versus 16-slice CCTA (60% vs. 84%, p ¼ 0.06).
CCTA versus IVUS. Four studies evaluated the presence
of any CAV by CCTA using IVUS as the reference test.
The CCTA was performed between 34 and 88 months
(mean 64months) after transplant. Themean heart rate at the
time of testing was 84 beats/min (range 77 to 90 beats/min).
The use of contrast media ranged from 60 to 100 ml and
the mean radiation dose was 10 mSv. No cases of contrast
induced nephropathy occurred in the enrolled patients. Three
studies used an intimal thickness >0.5 mm to determine the
presence of CAV, whereas 1 study used the presence of
“proliferative changes” to determine the presence of CAV
(Table 1).
PATIENT-BASED ANALYSIS. Sixteen patients were found to
have CAV by IVUS, representing a prevalence of 80%. The
weighted mean sensitivity and speciﬁcity of 64-slice CCTA
were 81% (95% CI: 57% to 93%) and 75% (95% CI: 30% to
95%), whereas the PPV was 93% (95% CI: 68% to 99%) and
NPV was 50% (95% CI: 19% to 81%). This technique had a
mean weighted accuracy of 80% (95% CI: 58% to 92%).
There were no studies evaluating the diagnostic accuracy of
16-slice CCTA using a patient-based analysis.
Figure 3
Diagnostic Accuracy of CCTA for the Evaluation of the Presence of Any CAV Using a
Patient-Based Analysis and CCAG as Reference Test
Forest plots of the sensitivity, speciﬁcity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy of coronary computed tomography angiography
(CCTA) stratiﬁed by number of slices (16-slice and 64-slice CCTA). The size of the square-plotting symbol is proportional to the same size for each study. Horizontal lines are the
95% conﬁdence intervals (CIs). Hierarchical summary receiver operating characteristic (HSROC) plot (CCTA: 64þ16). On the basis of combined sensitivity and speciﬁcity
weighted for sample size of each data set reﬂected by the size of the circles, showing average sensitivity and speciﬁcity estimate of the study results (solid square) and 95%
conﬁdence region around it. The 95% prediction region represents the conﬁdence region for a forecast of the true sensitivity and speciﬁcity in a future study. CAV ¼ cardiac
allograft vasculopathy; CCAG ¼ conventional coronary angiography; ES ¼ effect size.
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Table 2
Summary Estimates for Weighted Mean Sensitivity,
Speciﬁcity, PPV, NPV, and Accuracy of CCTA for
the Evaluation of the Presence of Any CAV Compared
With CCAG
Weighted Mean Overall
64-Slice
CCTA
16-Slice
CCTA p Value
A. Patient-based
analysis
n ¼ 203 n ¼ 149 n ¼ 54
Sensitivity 97 (92–100) 98 (94–100) 91 (78–100) 0.51
Speciﬁcity 81 (74–88) 79 (71–87) 84 (72–97) 0.52
PPV 78 (71–86) 78 (69–87) 81 (66–95) 0.43
NPV 97 (92–100) 98 (94–100) 93 (82–100) 0.52
Accuracy 88 (84–93) 87 (82–93) 90 (82–98) 0.45
B. Segment-based
analysis
n ¼ 2,883 n ¼ 2,424 n ¼ 459
Sensitivity 88 (85–92) 89 (85–92) 88 (81–95) 0.28
Speciﬁcity 89 (88–90) 90 (89–91) 85 (82–89) 0.89
PPV 55 (51–59) 55 (51–59) 56 (47–64) 0.71
NPV 98 (97–98) 98 (98–99) 96 (94–98) 0.26
Accuracy 90 (89–91) 90 (89–92) 85 (82–88) 0.22
Values are % (95% conﬁdence interval).
CAV ¼ cardiac allograft vasculopathy; CCAG ¼ conventional coronary angiography;
CCTA ¼ coronary computed tomography angiography; NPV ¼ negative predictive value;
PPV ¼ positive predictive value.
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1999SEGMENT-BASED ANALYSIS. A total of 204 segments had
CAV by IVUS, representing a prevalence of 34%. The
combined overall weighted mean sensitivity, speciﬁcity,
PPV, NPV and accuracy for CCTA (64-slice and 16-slice,
n ¼ 836 segments) were 89% (95% CI: 86% to 93%), 89%
(95% CI: 87% to 92%), 79% (95% CI: 74% to 83%), 94%
(95% CI: 92% to 96%), and 90% (95% CI: 88% to 92%),
respectively (Fig. 5). The weighted mean sensitivity and
speciﬁcity of 64-slice (n ¼ 229 segments) versus 16-slice
CCTA (n ¼ 607 segments) were 78% (95% CI: 70% to
86%) versus 94% (95% CI: 91% to 98%, p ¼ 0.08) and 88%
(95% CI: 83% to 94%) versus 90% (95% CI: 87% to 92%,
p ¼ 0.90), whereas the PPV was 82% (95% CI: 74% to 90%)
versus 77% (95% CI: 71% to 82%, p ¼ 0.43), and NPV was
83% (95% CI: 77% to 90%) versus 98% (95% CI: 96% to
99%, p ¼ 0.07), respectively. There was no signiﬁcant dif-
ference in mean weighted accuracy between 64-slice 83%
(95% CI: 78% to 88%) and 16-slice CCTA 91% (95%
CI: 89% to 93%, p ¼ 0.58).Discussion
In the present meta-analysis, we focused on the diagnostic
performance of the newest generation of CCTA (16 slices)
to assess the extent and severity of CAV compared with the
clinical standard of CCAG, and with the highly sensitive
IVUS. The main result of our study is the demonstration of
high sensitivity, speciﬁcity and NPV of CCTA for the
diagnosis of CAV when compared with the clinical standard
CCAG. The high sensitivity and NPV suggest that a
negative CCTA can accurately exclude CAV in the absolute
majority of heart transplant recipients undergoing this test.
As expected, the sensitivity and NPV of CCTA to detectCAV were lower when the highly sensitive IVUS was used
as the standard reference test.
CAV is a progressive disorder that is characterized by
diffuse concentric intimal hyperplasia involving both
epicardial and intramyocardial arteries (33,34). It is difﬁcult
to diagnose in the early stages as it is typically silent in
the denervated transplanted heart, and ischemia or graft
dysfunction are usually not evident until the disease is
advanced and manifests as heart failure, arrhythmias or
sudden death. Yearly screening to detect CAV before graft
injury results is therefore recommended (13). Noninvasive
stress testing such as exercise electrocardiography, stress
echocardiography, and single-photon emission computed
tomography have been used, however, the modest diagnostic
accuracy is a major limitation of these tests (35), and thus
clinical guidelines recommend CCAG as a screening tool
for CAV (13). Although CCAG has an important role in
the clinical assessment of the severity, progression, and
classiﬁcation of CAV, it often underestimates the extent and
severity of CAV as a consequence of the vascular remodeling
process (36,37). Histopathologic studies have shown that as
many as 73% of angiographically normal segments have mild
to moderate ﬁbrous intimal thickening by light microscopy
(38). Addition of coronary IVUS allows for detection and
quantiﬁcation of intimal hyperplasia by imaging of the vessel
wall structure, making it the most sensitive test for detecting
CAV. At 4 years after transplantation, CCAG detects CAV
in one-third of recipients, whereas diagnosis of CAV is
made in 55% by IVUS (37). However, the drawbacks of
IVUS are its invasiveness, limitation to assessment of only
proximal epicardial arteries, risk of serious complications and
cost (39). Although the rate of progression and CAV
severity as assessed by IVUS has been shown to have
prognostic implications as far as the risk of myocardial
infarction, heart failure, retransplantation and death (40,41),
the detailed information provided by IVUS does not trigger
changes in clinical care that would alter patient outcomes.
Therefore, addition of IVUS to screening CCAG has not
become the standard approach to CAV screening.
CCTA is a noninvasive technique that permits quantiﬁ-
cation of lumen size and wall vessel structure. Its diagnostic
accuracy has been extensively studied in large study groups
of nontransplanted patients (42). However, the small
number of studies evaluating the accuracy of CCTA to
detect CAV has included only limited number of patients
(6–9,25,26,30–32). The aim of our meta-analysis was to
determine whether data pooled from prospectively con-
ducted studies could provide a stronger basis for clinical
application of CCTA in transplant recipients. Although
the results were consistent when analyzed as individual
coronary segments, or when assessed on the basis of an
overall test result in each patient, the main clinical im-
plications can be drawn from the patient-based data.
Using CCAG as the reference test, CCTA has an
excellent sensitivity and NPV for the diagnosis of CAV,
being 94% and 99% for the detection of signiﬁcant CAV
Figure 4
Diagnostic Accuracy of CCTA for the Evaluation of the Presence of Signiﬁcant CAV Using a
Patient-Based Analysis and CCAG as Reference Test
Forest plotsof thesensitivity, speciﬁcity, PPV,NPV, anddiagnostic accuracy ofCCTAstratiﬁedbynumber of slices (16-slice and64-sliceCCTA). The size of thesquare-plotting symbol
is proportional to the samesize for eachstudy.Horizontal linesare the95%CIs. HSROCplot (CCTA:64þ16).On the basis of combined sensitivity andspeciﬁcity weighted for sample
size of each data set reﬂected by the size of the circles, showing average sensitivity and speciﬁcity estimate of the study results (solid square) and 95% conﬁdence region around it.
The 95% prediction region represents the conﬁdence region for a forecast of the true sensitivity and speciﬁcity in a future study. Abbreviations as in Figure 3.
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Table 3
Summary Estimates for Weighted Mean Sensitivity,
Speciﬁcity, PPV, NPV, and Accuracy of CCTA for the
Evaluation of Signiﬁcant CAV Compared With CCAG
Weighted Mean Overall
64-Slice
CCTA
16-Slice
CCTA p Value
A. Patient-based
analysis
n ¼ 392 n ¼ 241 n ¼ 151
Sensitivity 94 (87–100) 97 (88–100) 91 (81–100) 0.06
Speciﬁcity 92 (89–95) 92 (89–96) 92 (86–96) 1.00
PPV 67 (59–76) 63 (52–74) 72 (60–85) 0.06
NPV 99 (97–100) 99 (97–100) 97 (93–100) 0.06
Accuracy 94 (91–96) 94 (91–97) 93 (88–97) 0.37
B. Segment-based
analysis
n ¼ 5,762 n ¼ 3,296 n ¼ 2,466
Sensitivity 86 (82–91) 89 (82–97) 84 (77–89) 0.87
Speciﬁcity 99 (98–99) 99 (98–99) 99 (99–100) 0.97
PPV 73 (68–78) 60 (51–68) 84 (78–90) 0.06
NPV 99 (99–100) 100 (99–100) 99 (99–100) 0.31
Accuracy 99 (98–99) 98 (98–99) 99 (98–99) 0.98
Values are % (95% conﬁdence interval).
Abbreviations as in Table 2.
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2001and 97% for the presence of any CAV. Compared with
16-slice CCTA, the use of 64-slice CCTA was associated
with a strong trend toward improved sensitivity and NPV
for the detection of signiﬁcant CAV, likely the result of
better spatial and temporal resolution. These results are
clinically important as indicate that CCTA could be used
effectively as a gatekeeper to CCAG, thus reducing the
number of downstream tests and procedures, CCAG-
related complications and costs, as prior experience in
the general population suggests (43,44). The speciﬁcity
and PPV of CCTA for the evaluation of the presence of
any CAV were modest, a ﬁnding that can be explained by
the low sensitivity of CCAG, related to its inability to
evaluate the vessel wall. As expected, the speciﬁcity of
CCTA to detect signiﬁcant CAV was higher than for the
evaluation of the presence of any CAV. Although the
speciﬁcity of CCTA to detect signiﬁcant CAV was
excellent, the PPV remain modest likely as a consequence
of the low prevalence of signiﬁcant CAV lesions.
The segment-based results are important from the tech-
nical perspective. These results showed an excellent sensi-
tivity and NPV of CCTA to detect both, the presence of any
CAV and the presence of signiﬁcant CAV, conﬁrming the
high diagnostic accuracy of this technique.
The routine use of CCTA for the assessment of CAV is
not supported by current clinical guidelines (13), as a result
of not only the limited data on its diagnostic accuracy, but
also due to limited data evaluating its prognostic value on
post-transplant survival. More recently, Rohnean et al. (19)
prospectively evaluated 62 heart transplant recipients by
means of serial CCTA and showed that this technology
provides a safe and reliable alternative to CCAG for the
long-term evaluation of CAV. After 5 years, 30% of pa-
tients with a normal CCTA at baseline progressed to
develop wall thickening (24%) or signiﬁcant stenosis (6%),whereas 22% of patients with wall thickening at baseline
progressed to develop signiﬁcant stenosis. More impor-
tantly, there were no major coronary events during the study
period, suggesting that no patients were classiﬁed as false-
negatives by CCTA and further supporting its high sensi-
tivity and NPV (19).
An added diagnostic advantage of CCTA over CCAG
is the ability to visualize both the lumen and the vessel
wall. In our analysis, CCTA showed a good diagnostic
accuracy in comparison with IVUS, the most sensitive and
speciﬁc method for detecting early coronary artery disease
and CAV. It is possible that these ﬁndings might have
important clinical implications as use of certain immu-
nosuppressant agents (e.g., proliferative signal inhibitors)
have been associated with reduced incidence and slower
progression of CAV (45). Further, vessel wall character-
ization may also provide mechanistic insights into the
disease process underlying CAV. Our group has recently
reported histopathologic differences in vascular remodel-
ing between native coronary artery disease and CAV,
showing that outward vessel remodeling, a phenotype
more frequently associated with vulnerable lesions, was
reduced in CAV compared with native coronary artery
disease, likely the result of both accelerated intimal
ingrowth and limited outward remodeling in CAV (46).
The effective radiation dose and total amount of iodin-
ated contrast agent administered during CCTA testing
could be of concern if implemented as a repeated annual
assessment. In this meta-analysis, the reported dose of ra-
diation was 3 to 18 mSv and use of contrast media was 60
to 115 ml, which are somewhat higher compared
with CCAG. The development of newer techniques
including acquisition protocols using high-pitch spiral scan
(Flash Spiral mode), step and shoot protocols targeting the
systolic phase of the cardiac cycle and reduced-dose low
voltage CCTA with sonogram-afﬁrmed iterative recon-
struction are expected to reduce radiation and contrast dose
to approximately 1 mSv and 10 ml per study, respectively
(47–49). It is also conceivable that in those patients with
none or minimal vasculopathy, on the basis of the high
sensitivity and NPV of CCTA, the interval between
screening tests could be increased. In addition, contrast
induced nephropathy was not observed in any of the eval-
uated patients, although this might have been the result of a
selection bias in the analyzed studies.
Study limitations. The results of our study are limited to a
select group of heart transplant recipients. Patients with
chronic kidney disease were excluded from the majority
of the studies and no patients with a serum creatinine
>2.8 mg/dl were included. Nonetheless, this remains a
limitation as well for the reference test CCAG. Patients with
cardiac arrhythmias were also excluded. Further, the
ability of CCTA to evaluate small distant branches is
limited. Recognizing this limitation, none of the evaluated
studies included segments <15 mm in diameter, where
CAV is commonly recognized in its early stages.
Figure 5
Diagnostic Accuracy of CCTA for the Evaluation of the Presence of Any CAV Using a Segment-Based Analysis and IVUS as
Reference Test
Forest plots of the sensitivity, speciﬁcity, PPV, NPV, and diagnostic accuracy of CCTA stratiﬁed by number of slices (16-slice and 64-slice CCTA). The size of the square-plotting
symbol is proportional to the same size for each study. Horizontal lines are the 95% CIs. HSROC plot (CCTA: 64þ16). On the basis of combined sensitivity and speciﬁcity
weighted for sample size of each data set reﬂected by the size of the circles, showing average sensitivity and speciﬁcity estimate of the study results (solid square) and 95%
conﬁdence region around it. The 95% prediction region represents the conﬁdence region for a forecast of the true sensitivity and speciﬁcity in a future study. IVUS¼ intravascular
ultrasound; other abbreviations as in Figure 3.
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2003Conclusions
In this meta-analysis, CCTA demonstrated to be a robust
technique for the diagnosis of CAV. Its excellent sensitivity
and NPV suggest that CAV can be accurately excluded with
this noninvasive test, thus avoiding invasive procedures. In
light of these results, CCTA should be considered as an
alternative to CCAG for CAV screening in the routine care
of heart transplant recipients.
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